Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF‑mutated metastatic colorectal cancer: The BEETS (JACCRO CC‑18) study.

Key Points

• The aim is to evaluate the real-world survival outcomes of encorafenib, cetuximab, and binimetinib in BRAF-mutated metastatic colorectal cancer.
• Analyzed real-world clinical data from the BEETS study
• Compared survival outcomes of triplet therapy to doublet therapy
• Focused on patients with BRAF mutations
• Triplet and doublet therapies showed similar survival outcomes
• Potential benefits identified for triplet therapy in patients with poor performance factors
• Findings align with previous results from the BEACON trial